Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Downregulation of Rap1Gap: A Switch from DCIS to Invasive Breast Carcinoma via ERK/MAPK Activation.

Shah S, Brock EJ, Jackson RM, Ji K, Boerner JL, Sloane BF, Mattingly RR.

Neoplasia. 2018 Sep;20(9):951-963. doi: 10.1016/j.neo.2018.07.002. Epub 2018 Aug 22.

2.

Evaluating the potential for maximized T cell redistribution entropy to improve abscopal responses to radiotherapy.

Walker R, Schoenfeld JD, Pilon-Thomas S, Poleszczuk J, Enderling H.

Converg Sci Phys Oncol. 2017 Sep;3(3). pii: 034001. doi: 10.1088/2057-1739/aa7269. Epub 2017 Jun 15.

3.

Ras and Rap1: A tale of two GTPases.

Shah S, Brock EJ, Ji K, Mattingly RR.

Semin Cancer Biol. 2018 Apr 3. pii: S1044-579X(18)30003-8. doi: 10.1016/j.semcancer.2018.03.005. [Epub ahead of print] Review.

PMID:
29621614
4.

Evolutionary advantage of directional symmetry breaking in self-replicating polymers.

Subramanian H, Gatenby RA.

J Theor Biol. 2018 Jun 7;446:128-136. doi: 10.1016/j.jtbi.2018.03.012. Epub 2018 Mar 12.

PMID:
29544886
5.

Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue.

Karolak A, Rejniak KA.

Bull Math Biol. 2018 Feb 8. doi: 10.1007/s11538-018-0402-x. [Epub ahead of print]

PMID:
29423880
6.

Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.

Gallaher JA, Enriquez-Navas PM, Luddy KA, Gatenby RA, Anderson ARA.

Cancer Res. 2018 Apr 15;78(8):2127-2139. doi: 10.1158/0008-5472.CAN-17-2649. Epub 2018 Jan 30.

PMID:
29382708
7.

Systematic Screening of Chemokines to Identify Candidates to Model and Create Ectopic Lymph Node Structures for Cancer Immunotherapy.

Yagawa Y, Robertson-Tessi M, Zhou SL, Anderson ARA, Mulé JJ, Mailloux AW.

Sci Rep. 2017 Nov 22;7(1):15996. doi: 10.1038/s41598-017-15924-2.

8.

Classifying the evolutionary and ecological features of neoplasms.

Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D.

Nat Rev Cancer. 2017 Oct;17(10):605-619. doi: 10.1038/nrc.2017.69. Epub 2017 Sep 15. Review.

9.

MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma.

Emmons MF, Anreddy N, Cuevas J, Steinberger K, Yang S, McLaughlin M, Silva A, Hazlehurst LA.

Sci Rep. 2017 Jun 2;7(1):2685. doi: 10.1038/s41598-017-02713-0.

10.

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.

Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Di Liberto M, Moscinski LC, Koomen JM, Dalton WS, Shain KH, Wang M, Sotomayor E, Tao J.

Nat Commun. 2017 Apr 18;8:14920. doi: 10.1038/ncomms14920.

11.

An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma.

Silva A, Silva MC, Sudalagunta P, Distler A, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt C, Baz R, Perez L, Rebatchouk D, Dalton W, Greene J, Gatenby R, Gillies R, Sontag E, Meads MB, Shain KH.

Cancer Res. 2017 Jun 15;77(12):3336-3351. doi: 10.1158/0008-5472.CAN-17-0502. Epub 2017 Apr 11.

12.

Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer.

Gatenby RA, Brown J.

Biochim Biophys Acta Rev Cancer. 2017 Apr;1867(2):162-166. doi: 10.1016/j.bbcan.2017.03.005. Epub 2017 Mar 21. Review.

13.

Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.

Ibrahim-Hashim A, Robertson-Tessi M, Enriquez-Navas PM, Damaghi M, Balagurunathan Y, Wojtkowiak JW, Russell S, Yoonseok K, Lloyd MC, Bui MM, Brown JS, Anderson ARA, Gillies RJ, Gatenby RA.

Cancer Res. 2017 May 1;77(9):2242-2254. doi: 10.1158/0008-5472.CAN-16-2844. Epub 2017 Mar 1.

14.

Aggregation Effects and Population-Based Dynamics as a Source of Therapy Resistance in Cancer.

Brown JS, Cunningham JJ, Gatenby RA.

IEEE Trans Biomed Eng. 2017 Mar;64(3):512-518. doi: 10.1109/TBME.2016.2623564. Epub 2016 Nov 1.

15.

Stem Cell Plasticity and Niche Dynamics in Cancer Progression.

Picco N, Gatenby RA, Anderson ARA.

IEEE Trans Biomed Eng. 2017 Mar;64(3):528-537. doi: 10.1109/TBME.2016.2607183. Epub 2016 Sep 8.

16.

Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation.

Avnet S, Di Pompo G, Chano T, Errani C, Ibrahim-Hashim A, Gillies RJ, Donati DM, Baldini N.

Int J Cancer. 2017 Mar 15;140(6):1331-1345. doi: 10.1002/ijc.30540.

17.

Stochasticity in the Genotype-Phenotype Map: Implications for the Robustness and Persistence of Bet-Hedging.

Nichol D, Robertson-Tessi M, Jeavons P, Anderson AR.

Genetics. 2016 Dec;204(4):1523-1539. Epub 2016 Oct 21.

18.

Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.

Kim E, Rebecca VW, Smalley KS, Anderson AR.

Eur J Cancer. 2016 Nov;67:213-222. doi: 10.1016/j.ejca.2016.07.024. Epub 2016 Sep 28.

19.

Lysosomal protein relocation as an adaptation mechanism to extracellular acidosis.

Damaghi M, Gillies RJ.

Cell Cycle. 2016 Jul 2;15(13):1659-60. doi: 10.1080/15384101.2016.1176394. Epub 2016 Apr 20. No abstract available.

20.

Darwinian Dynamics of Intratumoral Heterogeneity: Not Solely Random Mutations but Also Variable Environmental Selection Forces.

Lloyd MC, Cunningham JJ, Bui MM, Gillies RJ, Brown JS, Gatenby RA.

Cancer Res. 2016 Jun 1;76(11):3136-44. doi: 10.1158/0008-5472.CAN-15-2962. Epub 2016 Mar 23.

Supplemental Content

Loading ...
Support Center